Indusatumab

Indusatumab is a monoclonal antibody designed for the treatment of cancer. It is a type of biological therapy that targets the tumor necrosis factor (TNF) family member TWEAK (TNF-like weak inducer of apoptosis).

Mechanism of Action

Indusatumab works by binding to the TWEAK receptor, Fn14, which is often overexpressed in many types of cancer. This binding inhibits the interaction of TWEAK with Fn14, thereby blocking the downstream signaling pathways that promote cancer cell growth and survival.

Clinical Trials

Indusatumab has been evaluated in several clinical trials for its safety and efficacy in treating various types of cancer. In a phase I clinical trial, indusatumab showed promising results in patients with advanced solid tumors. Further clinical trials are ongoing to determine the optimal dosing regimen and to evaluate the drug's efficacy in combination with other cancer therapies.

Side Effects

Like all drugs, indusatumab can cause side effects. The most common side effects reported in clinical trials include fatigue, nausea, and decreased appetite. Serious side effects can also occur, including allergic reactions and infusion-related reactions.

Future Directions

Research is ongoing to further understand the role of TWEAK and Fn14 in cancer and to explore the potential of indusatumab as a targeted therapy for other types of cancer.

See Also

• Monoclonal antibodies
• Biological therapy
• Tumor necrosis factor
• Clinical trial

‎

---

Translate: - East Asian 中文, 日本, 한국어, South Asian हिन्दी, தமிழ், తెలుగు, Urdu, ಕನ್ನಡ, Southeast Asian Indonesian, Vietnamese, Thai, မြန်မာဘာသာ, বাংলা
European español, Deutsch, français, Greek, português do Brasil, polski, română, русский, Nederlands, norsk, svenska, suomi, Italian
Middle Eastern & African عربى, Turkish, Persian, Hebrew, Afrikaans, isiZulu, Kiswahili,
Other Bulgarian, Hungarian, Czech, Swedish, മലയാളം, मराठी, ਪੰਜਾਬੀ, ગુજરાતી, Portuguese, Ukrainian